08:58 AM EDT, 03/25/2025 (MT Newswires) -- Charles River Laboratories International ( CRL ) and Valo Health said Tuesday they identified their first advanceable product candidate for lupus and other autoimmune diseases using Logica.

The companies said Logica, an AI-powered drug development program born from their strategic partnership, translates biological insights into optimized preclinical assets.

The Logica Advanceable Lead program combines Valo's DNA-encoded libraries and Opal Computational Platform with Charles River's high-throughput screening to produce advanceable leads, they said.

CRL shares were 0.8% higher in recent premarket activity.